logo
Does Joe Biden's Prostate Cancer Diagnosis Have You Concerned About Your Own Health?

Does Joe Biden's Prostate Cancer Diagnosis Have You Concerned About Your Own Health?

Yahoo19-05-2025

FORMER PRESIDENT JOSEPH R. Biden has been diagnosed with Stage 4 prostate cancer, his office announced on Sunday. The cancer has spread to his bones, as it commonly does in more aggressive forms.
Prostate cancer is one of the most common cancers in men. About one in eight men will be diagnosed with prostate cancer during their lifetime, and an estimated 288,300 new cases will emerge this year, according to the American Cancer Society. It's more common in Black men and in all men over 65.
It is generally slow-growing, and one of the big challenges with this cancer is that there are really no symptoms, especially early on, according to the American Cancer Society. By the time you do see symptoms, the cancer has likely reached an advanced stage.
However, there is a screening test for it. When this is done and prostate cancer is caught early, it is often highly treatable, says Daniel Spratt, M.D., a prostate cancer management expert and a professor in the Department of Radiation Oncology at the Case Western Reserve University School of Medicine.
Protect yourself against this common disease by getting screened (see the recommendations for when below) and learning to identify the common signs. Here's how.
"PROSTATE CANCER IS one of those conditions that could easily be caught early,' says John Lynam, D.O., an osteopathic physician in Florida who specializes in urology. 'Because of screening and testing, it has a high cure rate once caught early.'
This is especially important because there are no real early signs of prostate cancer, he says.
'Once prostate cancer causes symptoms, it is usually advanced and is often not curable at that point,' says Jonathan Shoag, M.D., a urologist and member of the Case Comprehensive Cancer Center Population and Cancer Prevention Program at Case Western Reserve University.
If there are warning signs of prostate cancer, they can include:
Blood in the urine or semen
Problems urinating—including feeling like you need to urinate more often or a slow or weak stream
Blocked urine
Loss of bladder or bowel control
Erectile dysfunction
Painful ejaculation
Pain in hips, back, ribs, or other areas
Weakness or numbness in the legs or feet
Fatigue
Unintentional weight loss
'Prostate cancer tends to spread to the bones, which can be painful, cause fractures, and limit mobility,' Dr. Shoag says.
Any time you notice any of these symptoms, visit your primary care doctor as soon as you can to get screened for prostate cancer, Dr. Lynam suggests.
Dr. Spratt says many prostate or urinary symptoms often have nothing to do with prostate cancer. So it's important to rule out other potential health issues.
INSTEAD OF WATCHING for signs of prostate cancer, which means it's reached an advanced stage, Dr. Lynam suggests getting regular screenings to catch it early.
'The hope is catching the cancer when it is still asymptomatic and relatively easy to treat,' Dr. Shoag explains.
Following the American Urological Association guidelines, all men should be screened for prostate cancer once they turn 50, says Larry Lipshultz, M.D., a urology professor at the Baylor College of Medicine and Men's Health urology adviser.
For men at a higher risk for prostate cancer, screening is recommended between ages 40 and 45. Those groups include Black men, people with a family history of the cancer, and those with a genetic predisposition, such as having the BRCA gene, Dr. Lipshultz says.
Screening involves getting a prostate-specific antigen, or PSA, blood test and a prostate exam, he says.
You should get re-screened every two to four years, according to AUA.
PROSTATE CANCER SCREENING typically involves two tests, Dr. Spratt says.
One is a digital rectal exam, where doctors feel the prostate gland for abnormalities. 'It's a quick and painless procedure,' he adds.
The other is a PSA blood test, which measures the amount of a protein that's produced by cancerous and noncancerous cells in the prostate. 'Elevated PSA levels can be an indicator of prostate issues, including cancer,' Dr. Spratt.
Men without prostate cancer typically have PSA levels of under 4 nanograms per milliliter (ng/mL), according to the American Cancer Society. PSA levels between 4 and 10 suggest you could have about a 25 percent chance of prostate cancer, and levels over 10 signal that your chance of having the cancer is more than 50 percent.
Some have argued that a PSA test alone is enough to diagnose prostate cancer, Dr. Lipshultz says, but both are needed.
'You see somebody who has a normal PSA, and you do a prostate exam, and there's cancer everywhere because it's so undifferentiated that it doesn't make the PSA,' he explains.
Undifferentiated cancer cells typically don't look or behave like the normal cells in tissues where they develop and may not produce much PSA.
Prostate cancer is one of the most curable diseases when caught early, Dr. Lynam says. In some cases, lower-grade prostate cancers can sometimes be safely monitored by your doctor without needing intervention.
'The most important message I can tell patients is to know your family history and get regular prostate cancer screening and checkups,' he says. 'We are serious when we say early detection can save your life.'
You Might Also Like
The Best Hair Growth Shampoos for Men to Buy Now
25 Vegetables That Are Surprising Sources of Protein

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Long-lasting HIV prevention shot heads toward approval
Long-lasting HIV prevention shot heads toward approval

Yahoo

time5 hours ago

  • Yahoo

Long-lasting HIV prevention shot heads toward approval

June 6 (UPI) -- A new vaccine to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month. If approved, the shot -- lenacapavir -- would be given twice a year and could be a big step forward in the fight against HIV. Drugmaker Gilead Sciences tested the shot in a study of women and girls. None of the participants who received the injections got HIV. That early success helped boost Gilead's stock by 73% over the past year, The Wall Street Journal reported. "We know it's challenging to take a daily pill for prevention, and we see an incredible opportunity here," said Johanna Mercier, Gilead's chief commercial officer Right now, more than 400,000 people in the United States use pills to prevent HIV, The Wall Street Journal added. These medications are referred to as PrEP, short for pre-exposure prophylaxis. Gilead expects the number of users to top 1 million by the next decade. Many people already say they'd prefer a shot over daily pills. In one survey of more than 500 PrEP users, 95% said they would switch to a long-acting injection. Sales of other long-acting options, like the shot Apretude from GSK, have risen sharply - up 63% in the past year. Even with strong results, Gilead faces several hurdles. One is reaching the people who need PrEP the most. Black Americans represent 39% of new HIV cases but only 14% of current PrEP users. Many people still face stigma or lack insurance coverage, which can limit access. Gilead says reaching underserved groups is a top goal. Most current PrEP users have commercial insurance, but Medicaid will be key for expanding access to lower-income communities. Another concern: Some experts worry the new shot may simply replace current Gilead products, like the daily pill Descovy, which now holds about 40% to 45% of the market. But Gilead says the shot should help expand the overall number of people using PrEP in both the U.S. and abroad. "We're thinking globally about the public health impact we can have," Mercier said. The company is working with governments and health groups in the United Kingdom and low-income countries to raise awareness and make these products more available. More information The National Institutes of Health has more on Pre-Exposure Prophylaxis (PrEP). Copyright © 2025 HealthDay. All rights reserved.

Changemakers and moneymakers: Nonprofits meet with funders for community change
Changemakers and moneymakers: Nonprofits meet with funders for community change

Miami Herald

time6 hours ago

  • Miami Herald

Changemakers and moneymakers: Nonprofits meet with funders for community change

Ashley Eubanks Johnson never imagined she would find her calling on a highway off-ramp. While commuting home from work one evening in 2016, a homeless woman weaved through cars at a Pompano Beach stoplight to ask for change, her pants stained with blood due to her period. 'That really shocked me because the area we were in was down the street from a shelter,' admitted a now-38-year-old Eubanks Johnson. '[I] started calling around to different shelters, facilities and organizations that serve those that are unhoused and found little to no help or refuge for menstruators in need.' Shortly after, she took the money set aside for her 30th birthday trip to Jamaica and kickstarted The Beauty Initiative, a nonprofit that donates hygiene essentials like pads and tampons to women and girls in need. READ MORE: Nonprofit provides homeless women with help — and free sanitary hygiene items In the years since, Eubanks Johnson has revolutionized period-care awareness in greater Miami, touting her nonprofit's donation of 77,000 menstrual-care products to Miami-Dade County and Broward County schools this academic year, but the road to success has been bumpy. She has had to juggle her day job as a community liaison and database administrator for Broward County Public Schools alongside her community work for nearly a decade, occasionally dipping into her own paychecks to support the cause. 'I've done this work for almost nine years with no money, my money, and now some sponsorship money,' shares the Beauty Initiative CEO. Neglecting local grassroots nonprofits is an oversight that the world of philanthropy and one Miami-based organization are hoping to remedy. Changemakers and moneymakers A self-professed 'social impact accelerator,' Radical Partners' mission is to equip South Florida changemakers with the skills and funds needed to run a nonprofit and deploy them into their communities. The organization, which was established in 2012, pushes professional development and organizational management as part of the solution through initiatives such as Leadership Labs, a five-month program tailored to leaders who identify as Black, Indigenous or people of color. The other part of the solution? Rubbing elbows with moneymakers. In a Neighborhood Heroes Connect conference hosted by Radical Partners at the Phillip & Patricia Frost Museum of Science in Miami on June 5, The Beauty Initiative and other nonprofits met with JPMorgan Chase, TD Bank and other corporations to discuss the gaps in grassroots-nonprofit financing. Study findings released at the conference on the impact of Leadership Labs, whose curriculum promises networking opportunities with leaders in the nonprofit, for-profit and political sectors, revealed that the relationship between those funded and those funding is interdependent. Results from a survey conducted by Radical Partners showed that the improvements that nonprofits sought most aligned with what funders hoped to invest in. While most surveyed organizations reported fundraising, grant-writing help and optimized operational systems among their highest needs, funders reported innovative fundraising efforts and strong daily operations as the most attractive qualities when considering which groups to finance. 'There are things that you can achieve at a neighborhood level, where there's more trust and where, culturally, people understand the individuals they're working with,' said Ana Castillo, TD Bank's Florida regional community development manager. Castillo leverages her role to give marginalized communities in South Florida more access to traditional banking so they don't have to resort to risky financial moves such as payday loans. She says TD Bank's mission is accomplished, in part, by funding local organizations that understand their underserved neighborhoods best. Meanwhile, nonprofits such as the Foot Forward Foundation, founded by Broward-based Christopher Sisco and Maurizo Raponi, benefit from the spotlight that tends to follow funders. '[We want] just a little bit of visibility,' said Sisco, 41, who began the initiative in 2022 by handing out shoes from his own 'sneakerhead' collection to homeless people. The nonprofit has since expanded to serve low-income students and has launched six shoe-donation campaigns at schools across Broward and Miami-Dade in the past 18 months. 'We do what we do because we enjoy doing it, but [we hope] for more people with big pockets to see what Foot Forward is doing.' Creative solutions Championing collaboration between funders and nonprofit leaders, Radical Partners CEO Joana Godoy proposes what her organization calls 'creative solutions' to long-standing obstacles in the nonprofit sector. To alleviate the disparity between funders' donation caps and nonprofits' need for resources, Godoy suggests nonprofits share services and spaces — such as collectively pitching in for an accountant or having joint office areas — to spur teamwork while cutting costs. How to streamline administrative work when short-staffed? She recommends nonprofits look to how the business world has used artificial intelligence. 'We might die trying [to implement these solutions alone],' urged Godoy. 'So what we're offering here is, instead of putting everything on [ourselves], meaning 'my team, my organization, my funders,' for us to approach it as an ecosystem.' It's an outlook that changemakers such as Eubanks Johnson, who graduated from Leadership Labs' third cohort in 2019, have already begun to adopt and benefit from. '[Radical Partners gives] us the tools we need to lead, connects us with a community of trusted collaborators and . . . [helped me] lean into my gifts and trust myself,' shared Eubanks Johnson. 'With doing that, I was able to center my work in service with so many others.'

Long-lasting HIV prevention shot heads toward approval
Long-lasting HIV prevention shot heads toward approval

UPI

time6 hours ago

  • UPI

Long-lasting HIV prevention shot heads toward approval

June 6 (UPI) -- A new vaccine to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month. If approved, the shot -- lenacapavir -- would be given twice a year and could be a big step forward in the fight against HIV. Drugmaker Gilead Sciences tested the shot in a study of women and girls. None of the participants who received the injections got HIV. That early success helped boost Gilead's stock by 73% over the past year, The Wall Street Journal reported. "We know it's challenging to take a daily pill for prevention, and we see an incredible opportunity here," said Johanna Mercier, Gilead's chief commercial officer Right now, more than 400,000 people in the United States use pills to prevent HIV, The Wall Street Journal added. These medications are referred to as PrEP, short for pre-exposure prophylaxis. Gilead expects the number of users to top 1 million by the next decade. Many people already say they'd prefer a shot over daily pills. In one survey of more than 500 PrEP users, 95% said they would switch to a long-acting injection. Sales of other long-acting options, like the shot Apretude from GSK, have risen sharply - up 63% in the past year. Even with strong results, Gilead faces several hurdles. One is reaching the people who need PrEP the most. Black Americans represent 39% of new HIV cases but only 14% of current PrEP users. Many people still face stigma or lack insurance coverage, which can limit access. Gilead says reaching underserved groups is a top goal. Most current PrEP users have commercial insurance, but Medicaid will be key for expanding access to lower-income communities. Another concern: Some experts worry the new shot may simply replace current Gilead products, like the daily pill Descovy, which now holds about 40% to 45% of the market. But Gilead says the shot should help expand the overall number of people using PrEP in both the U.S. and abroad. "We're thinking globally about the public health impact we can have," Mercier said. The company is working with governments and health groups in the United Kingdom and low-income countries to raise awareness and make these products more available. More information The National Institutes of Health has more on Pre-Exposure Prophylaxis (PrEP). Copyright © 2025 HealthDay. All rights reserved.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store